Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
2期
提前终止
NCT06585150
| 适应症 | RSV Infection |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Gilead Sciences |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 150 人 |
|---|
| 干预（药物） | Obeldesivir, Obeldesivir Placebo |
|---|
| 开始日期 | 2024年10月14日 |
|---|
| 完成日期 | 2025年5月8日 |
|---|
| 结果公布日 | 2026年6月30日 |
|---|
摘要
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
Up to Day 15 · days
| Obeldesivir | 3.2 days |
|---|
| Placebo | 3.9 days |
|---|
| p-value | 0.2005 |
|---|
| Difference in median time | -0.7 |
|---|
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 13.5 percentage of participants |
|---|
| Placebo | 16.2 percentage of participants |
|---|
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 59.5 percentage of participants |
|---|
| Placebo | 57.5 percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。